Skip to main
CNTX
CNTX logo

CNTX Stock Forecast & Price Target

CNTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Context Therapeutics Inc. is making significant strides in its clinical-stage development of therapies for solid tumors, particularly focusing on female, hormone-dependent cancers, with the CTIM-76 program showing promising early clinical activity and a favorable safety profile. The company's robust pipeline, combined with a strong financial position that extends funding into 2027, provides a solid foundation for ongoing clinical evaluations and potential partnerships. Positive early dose escalation data and first-in-human signals suggest the potential for de-risking the development programs, indicating multiple value catalysts that could drive investor interest in the near term.

Bears say

Context Therapeutics Inc. reported a significant decrease in research and development expenses, dropping to $8.7 million from $16.8 million in Q3 2024, reflecting a lack of prior-year in-process charges tied to specific projects. Despite a reduction in net loss from $17.5 million to $9.7 million for Q3 2025, the company faces multiple risks that could adversely impact its financial stability, including potential safety concerns in clinical programs, competitive market pressures, and regulatory hurdles. Additionally, Context may require approximately $250 million in additional financing through 2041, with projections indicating a cash runway only through 2027, raising concerns about its longer-term viability and operation sustainability.

CNTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Context Therapeutics LLC (CNTX) Forecast

Analysts have given CNTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, CNTX has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Context Therapeutics LLC (CNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.